deltatrials
Terminated PHASE2 INTERVENTIONAL 4-arm NCT03566511

Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide

Sponsor: American Diabetes Association

Conditions Diabetes Mellitus, Type 2 Glucose Metabolism Disorders (Including Diabetes Mellitus) Glucose, High Blood
Interventions Diazoxide Placebo
Updated 18 times since 2018 Last updated: May 14, 2025 Started: Jun 12, 2018 Primary completion: Aug 1, 2020 Completion: Aug 1, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Grant funding ended. NIDDK grant renewed without an MR aim. No plans to do future studies.

Other terminated trials from American Diabetes Association

See all terminations from American Diabetes Association

Other Diabetes Mellitus, Type 2 trials with similar outcome

Browse all Diabetes Mellitus, Type 2 trials

This PHASE2 trial investigates Diabetes Mellitus, Type 2 and Glucose Metabolism Disorders (Including Diabetes Mellitus) and is currently terminated or withdrawn. American Diabetes Association leads this study, which shows 18 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~Oct 2019 · 8 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Jun 2020 · 5 months · monthly snapshot~Jun 2020 – ~Nov 2020 · 5 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Dec 2021 · 10 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Jul 2022 · 5 months · monthly snapshot~Jul 2022 – ~Jul 2023 · 12 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Terminated PHASE2

    Status: Suspended → Terminated

  3. Sep 2024 — Jun 2025 [monthly]

    Suspended PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE2

  5. Jul 2023 — Jul 2024 [monthly]

    Suspended PHASE2

    Status: Active Not Recruiting → Suspended

▶ Show 13 earlier versions

  1. Jul 2022 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Suspended → Active Not Recruiting

  2. Feb 2022 — Jul 2022 [monthly]

    Suspended PHASE2

  3. Dec 2021 — Feb 2022 [monthly]

    Suspended PHASE2

  4. Feb 2021 — Dec 2021 [monthly]

    Suspended PHASE2

  5. Jan 2021 — Feb 2021 [monthly]

    Suspended PHASE2

  6. Nov 2020 — Jan 2021 [monthly]

    Suspended PHASE2

  7. Jun 2020 — Nov 2020 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  8. Jan 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  9. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  10. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  11. Feb 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  12. Oct 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  13. Jul 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

    First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • American Diabetes Association
  • Meredith Hawkins
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Data source: Albert Einstein College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations